In a nationwide cohort study, exposure to anti-TNFα agents was associatedwith a decrease of the risk of acute arterial events as compared withunexposed patients (HR 0.79; 95%CI 0.66–0.95).125 Basic research reports that therapy targeting TNFα affects severalrisk factors associated with ASCVD. This evidence concerns the gene TNF and atherosclerosis.